Form 4: AEON Biopharma Director Jost Fischer Acquires Stock Options

Director Jost Fischer acquired 16,260 stock options in AEON Biopharma, Inc. on March 19, 2024.

Summary

• On March 19, 2024, Jost Fischer, a director of AEON Biopharma, Inc., was granted 16,260 stock options.
• The options have an exercise price of $14.40.
• The options vest in equal monthly installments over one year from the grant date, contingent upon continued service.
• Full vesting occurs upon a Change in Control of the Company.
• Following the transaction, Fischer directly owns 16,260 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation practice. The grant itself doesn't indicate positive or negative performance, but rather an incentive mechanism.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director to increase company value.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, director, AEON Biopharma, Form 4, beneficial ownership, securities